Xtant Medical Q1 revenue falls less than expected, outlook raised
Overview
U.S. spinal surgical solutions firm's Q1 revenue fell yr/yr but beat analyst expectations
Adjusted EPS for Q1 met analyst expectations
Company raised 2026 revenue guidance on new hemostatic product distribution agreement
Outlook
Xtant Medical raises 2026 revenue guidance to $101-$105 mln from $95-$99 mln
Company expects incremental revenue from Dilon's HEMOBLAST Bellows product in 2026
Company anticipates topline growth and margin expansion in 2026 and beyond
Result Drivers
ASSET SALE IMPACT - Revenue and operating expenses declined due to the sale of Coflex/CoFix assets and international hardware business to Companion Spine in December 2025
LOSS OF LICENSE REVENUE - Gross margin decreased mainly due to the cessation of high-margin Q-code and amniotic membrane license revenue at the end of 2025
Company press release: ID:nPn6ggQMHa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $20.9 mln | $20.16 mln (3 Analysts) |
Q1 EPS | Meet | -$0.02 | -$0.02 (3 Analysts) |
Q1 Net Income | Miss | -$3.10 mln | -$1.81 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Xtant Medical Holdings Inc is $1.20, about 137.9% above its May 12 closing price of $0.50
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.